This compound is a sulfonylurea derivative investigated as a pharmaceutical intermediate. It features an aromatic amide structure with ether and halogen substituents.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 16673-34-0
O-((Guanin-9-yl)methyl) acyclovir
Pharmaceutical intermediate
Glycinamide hydrochloride
pharmaceutical intermediate for peptide synthesis
Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH
Fmoc-protected amino acid for peptide synthesis
N-Fmoc-N-(2,4,6-trimethoxybenzyl)glycine
Pharmaceutical intermediate for peptide synthesis
Bezafibrate EP Impurity C
Pharmaceutical reference standard
Bézafibrate
antihyperlipoproteinemic active pharmaceutical ingredient
Alpha-(Benzoylamino)-4-hydroxy-N,N-dipropylbenzenepropanamide
Pharmaceutical intermediate for research
N--[4-(1-Methylethyl)benzoyl]-D-phenylalanine
Pharmaceutical intermediate for nateglinide
5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide
KVWWTCSJLGHLRM-UHFFFAOYSA-N
COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N